RE:RE:TH2101 This would also really help but parameters around the program and and u Delhi get possible valuation metric. Certainly narrows that unknown future value that we and the market don't quite have a handle on now. Putting that comp up there makes it really easy for analysts to justify rather large values.
Wino115 wrote:
This is strategically very ballsy! I haven't been able to read the new deck, but this is potentially huge. The reason? That cytotoxic is what is on the ADC Immunomedics created that was bought by Gilead for $21bil. And we know its name -Trodelvy. This would be the Trodelvy killer!
So the industry and FDA gushed over the Trodelvy science for mTNBC and it was approved after a brief P3 reading backed up the P2 data. But the toxin escapes and ends up in the digestive tract causing bad nausea and diarrhea. I believe the FDA sent back some of their early science trials because of that. So if this concentrates the drug in the tumor better with less effllux and better safety, it will crush Trodelvy. Absolutely kill it on day 1. Gilead needs $5bil+ annual revenue to justify their $21bil price tag. No way if this works.
This would prove up the entire platform for THTX and get AApproval for each program. So what do you pay for a platform that works on way more than one cancer type and with many CYTO toxins? Far more than $21bil in my book and I hope the BOD knows that!
jfm1330 wrote: On new information in the updated corporate presentation is the identity of a new PDC made out of TH19P01. It was given the codename TH2101, which likely mean it was the first research molecule made by Thera in 2021, jusy my guess. That being said, they also revealed with is the cytotoxic drud that is attached to TH19P01, and it is a molecule called SN38, which is the active metabolite of a drug called Irinotecan. This is a topoisomerase I inhibitor and it is 1000 times more active than irinotecan.
https://en.wikipedia.org/wiki/SN-38